UBS Global Biopharma Conference - BIOAGE LABS INC
Financial Performance:
- Holds approximately $350 million in cash, providing a runway through 2029.
- Current capital is allocated to fund the BGE-102 Phase 2 trial (QUAL-CV and Quell-DME), APJ agonist development through proof of concept, and potential additional NLRP3 indications.
Guidance and Future Outlook:
- BGE-102 Phase 2 data readout expected by the end of the current year.
- Quell-DME (Diabetic Macular Edema) Phase 2 readout projected for the second half of next year.
- IND filing for the first APJ agonist program targeted by the end of the year.
- Strategic focus shifts immediately toward ophthalmology and other de-risked indications, with cardiovascular outcomes trials deferred pending clearer signals from competitors (e.g., Artemis trial results).
Business Segments and Product Lines:
- Lead Program (BGE-102): Oral NLRP3 inhibitor with a novel binding site (distinct from ATPase pocket competitors); demonstrated 98% trough IL-1β suppression with placebo-like tolerability in Phase 1; high tissue distribution profile enables CNS and retinal penetration.
- Ophthalmology Strategy: Quell-DME trial evaluating BGE-102 as monotherapy and in combination with VEGF; aims to offer an oral alternative to intravitreal injections for patients resistant to injections or with incomplete VEGF control.
- Obesity/Longevity (APJ Agonists): Two programs (oral and parenteral) targeting Apelin Receptor; preclinical data suggests potential to double weight loss and restore body composition when combined with GLP-1s.
- Platform Partnerships: Collaboration with Lilly for therapeutic antibody development and with Novartis for target discovery linking aging biology, exercise benefits, and healthy longevity.
Market and Competitive Landscape:
- NLRP3 Competition: Differentiated by novel binding site and ability to trigger inflammasome disassembly, contrasting with competitors targeting the same ATPase pocket; ZILTI (IL-6) trial failure reinforces the potential superiority of upstream NLRP3 targeting.
- Ophthalmology Market: Addresses significant patient resistance to intravitreal injections (40% in "watch and wait" category) and offers a potential solution for VEGF-refractory patients.
- Obesity Market: Positioning APJ agonists as a weight-loss and muscle-preserving modality, capitalizing on high unmet need for mechanisms that preserve physical function.
Risks and Challenges:
- Strategic Pivot Risk: Abandoning near-term cardiovascular outcomes trials (ASCVD) delays potential blockbuster revenue; strategy depends on competitor data (e.g., Ventix, Artemis) validating the approach.
- Clinical Execution: Dependence on upcoming Phase 2 data to validate dose-response relationships and biomarker reductions; failure in Quell-DME could limit the ophthalmology beachhead.
- Safety Concerns: Previous APJ program faced liver safety signals; new programs utilize distinct chemotypes and lower dosing targets (<100mg) to mitigate idiosyncratic liver injury risks.
Management Commentary and Tone:
- Tone is confident regarding the scientific differentiation of BGE-102's unique binding mechanism and deep target inhibition.
- Management demonstrates pragmatism in pivoting away from high-risk, high-cost cardiovascular outcomes trials in the current capital environment, favoring indications with shorter timelines and de-risked biology.
- Emphasis on the "beachhead" strategy in ophthalmology to leverage the oral delivery advantage and tissue penetration.
Analyst Questions and Answers:
- Differentiation vs. Competitors: Confirmed unique binding site prevents cross-resistance and enables deeper inhibition compared to historical chemotypes; Phase 1 data shows superior biomarker suppression (86% CRP reduction).
- Impact of ZILTI Failure: Concluded that IL-6 is likely too downstream and a biomarker rather than a causal driver, reinforcing the strategic choice to target upstream NLRP3.
- DME Trial Design: Modeled after successful IL-6 trials (e.g., Mickey Bar) to show efficacy in 3 months; powered for 4-letter improvement in BCVA (better than the standard 1-line goal).
- APJ Safety: Clarified that the new program uses a completely novel chemotype and lower doses to avoid the liver toxicity seen in the prior Amgen-licensed program.
Other Key Points:
- BGE-102 is being evaluated in cohorts with obesity and elevated inflammation to assess metabolic benefits (liver fat, glucose control) alongside cardiovascular markers.
- Future NLRP3 pipeline may include Geographic Atrophy (GA) and Uveitic Macular Edema, following the de-risking of DME.
- The company's aging platform utilizes 50-year longitudinal data from global biobanks to identify longevity and physical function biomarkers.
- Company
- BIOAGE LABS INC
- Keywords
- BIOAGE LABS INC